AstraZeneca Agrees to Invest $2 Billion in Summit Cancer-Drug Developer

AstraZeneca announced on September 28, 2026, that it had agreed to invest $2 billion in newly issued Summit Therapeutics equity. The companies also signed a clinical collaboration to study combinations of Summit’s ivonescimab and AstraZeneca cancer medicines. The agreement is an investment and research partnership, not an acquisition or an approved new treatment.

What the companies agreed

AstraZeneca said its preferred shares would be convertible into Summit common stock, representing rights equivalent to about 12% of outstanding common shares after completion, or about 10.6% on a fully diluted basis. The company expected the equity closing within a week of the announcement, while a later conversion would require customary regulatory clearances. Those are announced expectations, not a confirmation that closing has occurred.

The first planned combination studies will pair ivonescimab, which targets PD-1 and VEGF, with AstraZeneca’s sonesitatug vedotin, an antibody-drug conjugate targeting CLDN18.2, in gastrointestinal cancers. Each company will supply its own medicine and share trial costs while retaining development and commercial rights to its respective product. They also signed a memorandum of understanding for possible broader testing with other AstraZeneca cancer medicines; that broader program is an intention rather than a finalized trial agreement.

Why it matters and what remains uncertain

The investment gives Summit funding and AstraZeneca a significant equity position while the two test whether the medicines work well together. Ivonescimab has approvals for certain lung cancer patients in China, but its U.S. application for a specific lung cancer use remains under FDA review, according to AstraZeneca. The newly proposed gastrointestinal combinations have not been shown by this announcement to be safe or effective.

Fierce Pharma’s September 29 industry report notes that the first agreement and the broader, nonbinding plan are separate parts of the deal. For another recent AskNovus finance report, see our coverage of CarMax’s fiscal second-quarter results.

Sources and image credit

AstraZeneca announcement (September 28, 2026), Summit Therapeutics announcement (September 28, 2026), and Fierce Pharma report (September 29, 2026). Featured image: illustrative laboratory photograph by Julia Koblitz / Unsplash; it does not depict this research program.